# ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

> **NCT02093741** · — · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 65 (actual)

## Conditions studied

- Hemophilia A
- Congenital Factor VIII (FVIII) Deficiency

## Interventions

- **BIOLOGICAL:** Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]

## Key facts

- **NCT ID:** NCT02093741
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-20
- **Primary completion:** 2016-01-20
- **Final completion:** 2016-01-20
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02093741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02093741, "ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02093741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*